PFDN2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10009(PFDN2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P10009(PFDN2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PFDN2 antibody targets the protein Prefoldin subunit 2 (PFDN2), a member of the prefoldin chaperone family. Prefoldins are molecular chaperones that assist in the folding of nascent polypeptides, particularly cytoskeletal components like actin and tubulin, by stabilizing unstructured regions and delivering them to group II chaperonins (e.g., TRiC/CCT) for proper folding. PFDN2. encoded by the *PFDN2* gene in humans, is one of six subunits (PFDN1-6) forming the hexameric prefoldin complex. Its structure features a β-barrel domain and coiled-coil regions, enabling interactions with unfolded proteins.

PFDN2 antibodies are widely used in research to study the protein's expression, localization, and interactions in cellular processes. Dysregulation of PFDN2 has been implicated in neurodegenerative diseases (e.g., Alzheimer’s) and cancers, where altered chaperone activity may contribute to protein aggregation or tumor progression. These antibodies are validated for techniques like Western blotting, immunofluorescence, and co-immunoprecipitation, aiding in mechanistic studies of PFDN2’s role in cell cycle regulation, stress response, and cytoskeletal dynamics. Commercial PFDN2 antibodies are typically raised against specific epitopes (e.g., human PFDN2 N-terminal regions) and verified for cross-reactivity across species. Research continues to explore its potential as a biomarker or therapeutic target in disease contexts.